Eupraxia Pharmaceuticals (NASDAQ:EPRX) Upgraded by RODMAN&RENSHAW to Strong-Buy Rating

RODMAN&RENSHAW upgraded shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) to a strong-buy rating in a report issued on Thursday morning,Zacks.com reports.

Separately, Rodman & Renshaw began coverage on shares of Eupraxia Pharmaceuticals in a research note on Thursday. They issued a “buy” rating and a $9.00 price objective on the stock.

Eupraxia Pharmaceuticals Stock Up 3.4 %

NASDAQ EPRX traded up $0.10 on Thursday, hitting $3.00. The company’s stock had a trading volume of 4,345 shares, compared to its average volume of 15,321. Eupraxia Pharmaceuticals has a 1-year low of $2.20 and a 1-year high of $5.58. The company’s 50-day moving average is $2.66 and its 200 day moving average is $2.68. The firm has a market cap of $81.84 million and a PE ratio of -4.08.

Institutional Trading of Eupraxia Pharmaceuticals

A hedge fund recently bought a new stake in Eupraxia Pharmaceuticals stock. 180 Wealth Advisors LLC bought a new position in shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 13,000 shares of the company’s stock, valued at approximately $34,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.